Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 594

Sort by

Sort Order Select

Journal Articles

Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH

Amel Sengal, Jessica Velazquez, Meryl Hahne, Thomas M. Burke, Harshal Abhyankar, Robert Reyes, Walter Olea, Brooks Scull, Olive S. Eckstein, Camille Bigenwald, Catherine M. Bollard, Wendong Yu, Miriam Merad, Kenneth L. McClain, Carl E. Allen, Rikhia Chakraborty

Blood (2021) 137 (13): 1777–1791.

https://doi.org/10.1182/blood.2020005867

Published: 2021

Includes: Supplemental data

Journal Articles

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Blood (2021) 137 (10): 1353–1364.

https://doi.org/10.1182/blood.2020006464

Published: 2021

Includes: Supplemental data

Journal Articles

Immune escape mechanisms for TCRLBCL

Wing C. Chan

Blood (2021) 137 (10): 1274–1276.

https://doi.org/10.1182/blood.2020008766

Published: 2021

Journal Articles

Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder

Christopher Melani, Elaine S. Jaffe, Wyndham H. Wilson

Blood (2020) 135 (16): 1344–1352.

https://doi.org/10.1182/blood.2019000933

Published: 2020

Journal Articles

Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling

Leandro Cerchietti, MD, Giorgio Inghirami, MD, Nikita Kotlov, PhD, Viktor Svekolkin, PhD, Alexander Bagaev, PhD, Felix Frenkel, PhD, Maria Victoria Revuelta, PhD, Jude M Phillip, PhD, Maria Teresa Cacciapuoti, MS, Sarah C. Rutherford, MD, Peter Martin, FRCPC, MD MS, John P. Leonard, MD

Blood (2019) 134 (Supplement_1): 656.

https://doi.org/10.1182/blood-2019-128889

Published: 2019

Journal Articles

A Complicated Neighborhood: Insights into the Hodgkin Lymphoma Microenvironment

Maher K. Gandhi, PhD

Blood (2019) 134 (Supplement_1): SCI-8.

https://doi.org/10.1182/blood-2019-121284

Published: 2019

Journal Articles

The Membrane Scaffold CD82 Regulates Acute Myeloid Leukemia Dormancy and Bone Marrow Niche Interactions

Muskan Floren, BS, Erica Pascetti, BS, Jennifer Gillette, PhD

Blood (2019) 134 (Supplement_1): 1396.

https://doi.org/10.1182/blood-2019-129320

Published: 2019

Journal Articles

Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma

Joshua C Pritchett, MD, Zhi-Zhang Yang, MD, Hyojin Kim, PhD, Jose C Villasboas, MD, Andrew L. Feldman, MD, James R. Cerhan, MD PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 1517.

https://doi.org/10.1182/blood-2019-131145

Published: 2019

Journal Articles

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

John E. Godwin, MD, Carmen Ballesteros-Merino, PhD, Nikhil Lonberg, Shawn Jensen, PhD, Tarsem Moudgil, Carlo B Bifulco, MD, Jon Wigginton, MD, John Muth, MS, Jan K Davidson-Moncada, MD PhD, Bernard Fox, PhD

Blood (2019) 134 (Supplement_1): 1410.

https://doi.org/10.1182/blood-2019-128485

Published: 2019

Journal Articles

Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

Blood (2019) 134 (Supplement_1): 2015.

https://doi.org/10.1182/blood-2019-126238

Published: 2019

Journal Articles

NUP98-HOXA9 -Initiates Molecular and Biologic Features of Disease Progression in a Humanized Model of CML

Ivan Sloma, PharmD, PhD, Philip Beer, PhD FRCPath, MRCP, Christophe Desterke, PhD, Elizabeth Bulaeva, Misha Bilenky, Michelle Moksa, Kamini Raghuram, Cedric Brimacombe, Karen Lambie, Ali G Turhan, MD PhD, Orianne Wagner-Ballon, MD PhD, Philippe Gaulard, MD PhD, R. Keith Humphries, MD PhD, Martin Hirst, PhD BS, Connie J. Eaves, PhD

Blood (2019) 134 (Supplement_1): 4139.

https://doi.org/10.1182/blood-2019-127839

Published: 2019

Journal Articles

Bleomycin Use in the Treatment of Hodgkin Lymphoma (HL): Toxicity and Outcomes in the Modern Era

Kekoa Taparra, PhD, Heshan Liu, PhD, Mei-Yin Polley, PhD, Kay M. Ristow, BS, Thomas M. Habermann, MD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 4038.

https://doi.org/10.1182/blood-2019-121488

Published: 2019

Journal Articles

Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma

Tessa Han, Stephane Minvielle, PhD, Anil Aktas Samur, PhD, Mariateresa Fulciniti, PhD, Florence Magrangeas, PhD, Paul G. Richardson, MD, Philippe Moreau, MD, Michel Attal, MD PhD, Kenneth C. Anderson, MD, Hervé Avet-Loiseau, MD PhD, Giovanni Parmigiani, PhD, Mehmet Kemal Samur, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4348.

https://doi.org/10.1182/blood-2019-130343

Published: 2019

Journal Articles

EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche

Wendy Béguelin, PhD, Matthew R Teater, PhD, Cem Meydan, PhD, Jude M Phillip, PhD, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 2768.

https://doi.org/10.1182/blood-2019-132263

Published: 2019

Journal Articles

Urine Proteomic Analysis Reveals Disease-Specific Patterns in Pediatric Patients with Classical Hodgkin's Disease(HD). an Addon Study to the Euronet-PHL-C2 Trial

Blood (2019) 134 (Supplement_1): 2804.

https://doi.org/10.1182/blood-2019-125611

Published: 2019

Journal Articles

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Danielle M. Brander, MD, John F. Seymour, MBBS, PhD FRACP, Thomas J. Kipps, MD PhD, Shuo Ma, MD PhD, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Michael Y. Choi, MD, Kathryn Humphrey, BSc, Abdullah Al Masud, PhD, Ruby Nandam, RN, MSN, Amanda Jacobson, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2019) 134 (Supplement_1): 3036.

https://doi.org/10.1182/blood-2019-126508

Published: 2019

Journal Articles

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma

Hongyu Zhang, MD PhD, Jia Feng, MD PhD, Wenli Zhang, MD, Qi Chen, PhD, Yuanzhen Cao, Kevin Pinz, Fang Liu, MD PhD, Yu Ma, Masayuki Wada, PhD, Yupo Ma, MD PhD

Blood (2019) 134 (Supplement_1): 2881.

https://doi.org/10.1182/blood-2019-122789

Published: 2019

Journal Articles

New Generation Chimeric Antigen Receptor T-Cell Therapy (CoupledCAR) Induces High Rate Remissions in Solid Tumor

Lei Xiao, PhD

Blood (2019) 134 (Supplement_1): 4631.

https://doi.org/10.1182/blood-2019-130703

Published: 2019

Journal Articles

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Rory M Shallis, MD, Jan Philipp Bewersdorf, MD, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Thomas Prebet, MD PhD, Steven D. Gore, MD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 1330.

https://doi.org/10.1182/blood-2019-127422

Published: 2019

Journal Articles

Interferon-γ-Dependent Inflammatory Signature in Acute Myeloid Leukemia Cells Is Able to Shape Stromal and Immune Bone Marrow Microenvironment

Marilena Ciciarello, PhD, Giulia Corradi, PhD, Sabina Sangaletti, PhD, Barbara Bassani, Giorgia Simonetti, PhD, Jayakumar Vadakekolathu, PhD, Giovanni Marconi, Giovanni Martinelli, MD, Mario Paolo Colombo, Sergio Rutella, MDPhDFRCPath, Michele Cavo, Antonio Curti, MD PhD

Blood (2019) 134 (Supplement_1): 1212.

https://doi.org/10.1182/blood-2019-126512

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Immune escape mechanisms for TCRLBCL

Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder

Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling

A Complicated Neighborhood: Insights into the Hodgkin Lymphoma Microenvironment

The Membrane Scaffold CD82 Regulates Acute Myeloid Leukemia Dormancy and Bone Marrow Niche Interactions

Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

NUP98-HOXA9 -Initiates Molecular and Biologic Features of Disease Progression in a Humanized Model of CML

Bleomycin Use in the Treatment of Hodgkin Lymphoma (HL): Toxicity and Outcomes in the Modern Era

Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma

EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche

Urine Proteomic Analysis Reveals Disease-Specific Patterns in Pediatric Patients with Classical Hodgkin's Disease(HD). an Addon Study to the Euronet-PHL-C2 Trial

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma

New Generation Chimeric Antigen Receptor T-Cell Therapy (CoupledCAR) Induces High Rate Remissions in Solid Tumor

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Interferon-γ-Dependent Inflammatory Signature in Acute Myeloid Leukemia Cells Is Able to Shape Stromal and Immune Bone Marrow Microenvironment

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only